Immunoglobulin A nephropathy (IgAN) is the most commonly encountered primary glomerulonephritis and it usually follows an indolent clinical course. However, hypertensive patients with proteinuria and renal insuf-ficiency at presentation and patients with severe histological involvement are at high risk to develop end-stage renal failure. Patients with normal renal function, mild proteinuria (<1 g/24h) and mild histopathological involvement need only observation, whereas patients with heavy proteinuria, impaired renal function and moderate to severe histopathological involvement are usually treated with immunosuppressive drugs. Angiotensin converting enzyme (ACE) inhibitors are used in patients with arterial hypertension and/or proteinuria 1–2 g/24h. Corticosteroids are indicated in patients with heavy proteinuria (>3 g/24h) and in progressive disease despite treatment with ACE inhibitors. Combinations of corticosteroids and cytotoxic drugs are saved for patients with IgA nephropathy and a rapidly progressive course. Fish oil might be an alternative to cor-ticosteroids in cases with renal insufficiency and chronic histological lesions.
BarrattJ., and FeehalyJ.IgA nephropathy.J Am Soc Nephrol2005; 16: 2088–97.
4.
HassM.Histological subclassification of IgA nephropathy. A clinicopathological study of 244 cases.Am J Kidney Dis1997; 29: 829–42.
5.
HaasM.J.Histology and immunohistology of IgA nephropathy.J Nephrol2005; 18: 676–80.
6.
D'AmicoG.Natural history of idiopathic IgA nephropathy and factors predictive of disease outcome.Semin Nephrol2004; 179–96.
7.
CoppoR., and D'AmicoG.Factors predicting progression of IgA nephropathies.J Nephrol2005; 18: 503–12.
8.
RobertsI.S., CookH.T., TroyanovS.Working Group of the International IgA Nephropathy Network and the Pathology Society. The Oxford classification of IgA nephropathy: pathology definitions, correlations and reproducibility.Kidney Int2009; 76: 546–56.
9.
CattranD.C., CoppoR., CookH.T.Working Group of the International IgA Nephropathy Network and the Pathology Society. The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations and classification.Kidney Int2009; 76: 534–45.
10.
CattranD.C., GreenwoodC., RitchieS.Long-term benefits of angiotensin-converting enzyme inhibitor therapy in patients with severe immunoglobulin A nephropathy: A comparison to patients receiving treatment with other antihypertensive agents and to patients receiving no therapy.Am J Kidney Dis1994; 23: 247–54.
11.
RuggenentiP., PernaA., GherardiG.Chronic proteinuric nephropathies: outcomes and response to treatment in a prospective cohort of 352 patients with different patterns of renal injury.Am J Kidney Dis2000; 35: 1155–65.
12.
PragaM., GutirrezE., GonzalezE.Treatment of IgA nephropathy with ACE inhibitors: A randomized and controlled trial.J Am Soc Nephrol2003; 14: 1578–83.
13.
CoppoR., PeruzziL., AmoreA.A placebo-controlled, randomized trial of angiotensin converting enzyme inhibitors in children and young people with IgA nephropathy and moderate proteinuria.J Am Soc Nephrol2007; 18: 1880–8.
14.
TominoY., KawamuraT., KimuraK.Antiproteinuric effect of olmesartan in patients with IgA nephropathy.J Nephrol2009; 22: 224–31.
15.
WooK.T., ChanC.M., TanH.K.Beneficial effect of high-dose losartan in IgA nephritis.Clin Nephrol2009; 71: 617–24.
16.
DillonJ.J.Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for IgA nephropathy.Semin Nephrol2004; 24: 218–24.
17.
HoritaY., TadokoroM., TauraK.Low-dose combination therapy with temocapril and losartan reduces proteinuria in normotensive patients with immunoglobulin A nephropathy.Hypertens Res2004; 27: 963–70.
18.
GrandeJ.P., WalkerH.J., HolubB.J.Suppressive effects of fish oil on mesangial cell proliferation in vitro and in vivo.Kidney Int2000; 57: 1027–40.
19.
HamazakiT., TatenoS., ShishidoH.Eicosapentanoic acid and IgA nephropathy.Lancet1984; 1: 1017–8.
20.
BennettW.M., WalkerR.G., Kincaid-SmithP.Treatment of IgA nephropathy with eicosapentanoic acid (EPA). A two-year prospective trial.Clin Nephrol1989; 31: 128–31.
21.
PetterssonE.E., RekolaS., BerglundL.Treatment of IgA nephropathy with omega-3-polyunsaturated fatty acids: a prospective double-blind randomized study.Clin Nephrol1994; 41: 183–90.
22.
ChengI.K., ChanP., ChanM.K.The effect of fish-oil dietary supplement in the progression of mesangial IgA glomerulonephritis.Nephrol Dial Transplant1990; 5: 241–6.
23.
DonadioJ.V., BergstralhE.J., OffordK.P.A controlled trial of fish oil in IgA nephropathy. Mayo Nephrology Collaborative Group.N Engl J Med1994; 331: 1194–9.
24.
DillonJ.J.Fish oil therapy for IgA nephropathy: Efficacy and inter-study variability.J Am Soc Nephrol1997; 8: 1739–44.
25.
DonadioJ.V., GrandeJ.R., BergstralhE.J.The long-term outcome of patients with IgA nephropathy treated with fish oil in a controlled trial. Mayo Nephrology Collaborative Group.J Am Soc Nephrol1999; 10: 1772–7.
26.
AlexopoulosE., StangouM., PantzakiA.Treatment of severe IgA nephropathy with omega-3 fatty acids: The effect of a ‘very low dose regimen’.Ren Fail2004; 26: 453–9.
27.
BrantenA.J., KlasenI.S., WetzelsJ.F.Short-term effects of fish oil treatment on urinary excretion of high- and low-molecular weight proteins in patients with IgA nephropathy.Clin Nephrol2002; 58: 267–74.
28.
HoggR.J., LeeJ., NardelliN.Clinical trial to evaluate omega-3 fatty acids and alternate day prednisolone in patients with IgA nephropathy: report from the Southwest Pediatric Nephrology Group.Clin J Am Soc Nephrol2006; 1: 467–74.
29.
HoggR.J., FitzgibbonsL., AtkinsC.; for the North American IgA Nephropathy Study Group. Efficacy of omega-3 fatty acids in children and adults with IgA nephropathy is dosage- and size-depend-ent.Clin J Am Soc Nephrol2006; 1: 1167–72.
30.
FerraroP.M., FerraccioliG.F., GambaroG.Combined treatment with renin-angiotensin system blockers and polyun-saturated fatty acids in proteinuric IgA nephropathy: a randomized controlled trial.Nephrol Dial Transplant2009; 24: 156–60.
31.
KomatsuH., FujimotoS., HaraS.Effect of tonsillectomy plus steroid therapy on clinical remission of IgA nephropathy: a controlled study.Clin J Am Soc Nephrol2008; 3: 1301–7.
32.
KawasakiY., SuyamaK., AbeY.Tonsillectomy with methylprednisolone pulse therapy as rescue treatment for steroid-resistant IgA nephropathy in children.Tohoku J Exp Med2009; 218: 11–6.
33.
PiccoliA., CodognottoM., TabbiM.G.Influence of tonsillectomy on the progression of mesangioproliferative glomerulonephritis.Nephrol Dial Transplant2010; (8): 2583–9.
34.
BuemiM., AllegraA., CoricaF.Effect of fluvastatin on proteinuria in patients with immunoglobulin A nephropathy.Clin Pharmacol Ther2000; 67: 427–31.
35.
KanoK., NishikuraK., YamadaY.Effect of fluvastatin and dipyridamole on proteinuria and renal function in childhood IgA nephropathy with mild histological findings and moderate proteinuria.Clin Nephrol2003; 60: 85–9.
36.
SzetoC.C., ChowK.M., KwanB.C.Oral calcitriol for treatment of persistent proteinuria in immunoglobulin A nephropathy: an uncontrolled trial.Am J Kidney Dis2008; 51: 724–31.
37.
LaiK.N., LaiI.M., HoC.P.Corticosteroid therapy in IgA nephropathy with nephrotic syndrome: a long-term controlled trial.Clin Nephrol1986; 26: 174–80.
38.
KobayashiY., HikiY., KokuboT.Steroid therapy during the early stage of progressive IgA nephropathy. A 10-year follow-up study.Nephron1996; 72: 237–42.
39.
PozziC., BolascoP.G., FogazziG.B.Corticosteroids in IgA nephropathy: a randomized controlled trial.Lancet1999; 353: 883–7.
40.
PozziC., AndrulliS., Del VecchioL.Corticosteroid effectiveness in IgA nephropathy: Long-term results of a randomized controlled trial.J Am Soc Nephrol2004; 15: 157–63.
41.
ShojiT., NakanishiI., SuzukiA.Early treatment with corticosteroids ameliorates proteinuria, proliferative lesions and mesangial phenotypic modulation in adult diffuse proliferative IgA nephropathy.Am J Kidney Dis2000; 35: 194–201.
42.
KatafuchiR., IkedaK., MizumasaT.Controlled prospective trial of steroid treatment in IgA nephropathy: a limitation of low-dose prednisolone therapy.Am J Kidney Dis2003; 41: 972–83.
43.
KatafuchiR., NikomiyaT., MizumasaT.The improvement of renal survival with steroid pulse therapy in IgA nephropathy.Nephrol Dial Transplant2008; 23: 3915–20.
44.
SamuelsJ.A., StrippoliG.F., CraigJ.C.Immunosuppressive treatments for immunoglobulin a nephropathy: a meta-analysis of randomized controlled trials.Nephrology2004; 9: 177–85.
45.
SuzukiS., and KensukeJ.Applicability of steroid therapy in 275 adult patients with IgA nephropathy using a histological scoring system and degree of proteinuria.Clin Exp Nephrol2004; 8: 109–16.
46.
RoccatelloD., FerroM., CoppoR.Report on intensive treatment of extracapillary glomerulonephritis with focus on crescentic IgA nephropathy.Nephrol Dial Transplant1995; 10: 2054–9.
47.
TumlinJ.A., LohavichanV., HennigarR.Crescentic, proliferative IgA nephropathy. Clinical and histological response to methylprednisolone and intravenous cyclophosphamide.Nephrol Dial Transplant2003; 18: 1321–9.
48.
BallardieF.W., RobertsI.S.Controlled prospective trial of prednisolone and cytotoxics in progressive IgA nephropathy.J Am Soc Nephrol2002; 13: 142–8.
49.
RascheF.M., KlotzC.H., CzockD.Cyclophosphamide pulse therapy in advanced progressive IgA nephropathy.Nephron Clin Pract2003; 93: 131–6.
50.
GoumenosD., DavlourosP., El NahasA.M.Prednisolone and azathioprine in IgA nephropathy?Nephron Clin Pract2003; 93: C58–C68.
51.
YoshikawaN., HondaM., IijimaK.; for the Japanese Pediatric IgA Nephropathy Treatment Study Group. Steroid treatment for severe childhood IgA nephropathy: a randomized controlled trial.J Am Soc Nephrol2006; 1: 511–7.
52.
PozziC., Del VecchioL., AndrulliS.Steroids and azathioprine vs. steroids alone in IgA nephropathy.Nephrol Dial Transplant2006; 22: Abstract FO020, vi10.
53.
OshimaS., and KawamuraO.Long-term follow-up of patients with IgA nephropathy treated with prednisolone and cyclophos-phamide therapy.Clin Exp Nephrol2008; 12: 264–9.
54.
ChenX., ChenP., CaiG.A randomized control trial of mycophenolate mofetil treatment in severe IgA nephropathy.Zhonghua Yi Xue Za Zhi2002; 82: 796–801.
55.
TangS.C., LeungJ.C., ChanL.Y.Mycophenolate mofetil alleviates persistent proteinuria in IgA nephropathy.Kidney Int2005; 85: 802–12.
56.
TangS.C., TangA.W., WongS.S.Long-term study of mycophenolate mofetil treatment in IgA nephropathy.Kidney Int2010; 77: 543–9.
57.
MayesB.D., OyenR., ClaesK.Mycophenolate mofetil in IgA nephropathy: Results of a 3-year prospective place-bo-contolled randomized study.Kidney Int2004; 65: 1842–9.
58.
FrischG., LinJ., RosenstockJ.Mycophenolate mofetil (MMF) vs placebo in patients with moderately advanced IgA nephropathy: a double-blind randomized controlled trial.Nephrol Dial Transplant2005; 20: 2139–45.
59.
NavaneethamS.D., ViswanathanG., StrippoliG.F.M.Meta-analysis of mycophenolate mofetil in IgA nephropathy.Nephrology2008; 13: 90.
60.
Del CantonA., AmoreA., BarbanoG.One year angiotensin converting enzyme inhibition plus mycophenolate mofetil immunosuppression in the course of early IgA nephropathy: a multicenter, randomized, controlled study.J Nephrol2005; 18: 136–40.
61.
LvJ., ZhangH., ChenY.Combination therapy of prednisone and ACE inhibitor versus ACE-inhibitor therapy alone in patients with IgA nephropathy: a randomized controlled trial.Am J Kidney Dis2009; 53: 26–32.
62.
MannoC., TorresD.D., RossiniM.Randomized controlled clinical trial of corticosteroid plus ACE – inhibitors with long-term follow-up in proteinuric IgA nephropathy.Nephrol Dial Transplant2009; 24: 3649–701.
63.
GerolymosM., KalliakmaniP., ChronolpolouI.Treatment of IgA nephropathy based on the severity of clinical and histological features. Preliminary results.World Congress Nephrology2009. Satellite Symposium on igA nephropathy May 26–28, 2009 Stresa, Italy.
64.
TanakaH., SuzukiK., NakahataT.Combined therapy of enalapril and losartan attenuates histologic progression in immunoglobulin A nephropathy.Pediatrics International2004; 46: 576–9.
65.
EitnerF., AckermannD., HigersR.D.Supportive Versus Immunosuppressive Therapy of Progressive IgA nephropathy (STOP) IgAN trial: rationale and study protocol.J Nephrol2008; 21: 284–9.
